These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19191294)

  • 1. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
    Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
    Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
    Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
    Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions.
    Wu GP; Zhang SS; Fang CQ; Liu SL; Wang EH
    Cytopathology; 2008 Aug; 19(4):212-7. PubMed ID: 18699986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
    Rahmani A; Dehghani MZ; Afshar NM; Heidarian H; Tahririan R
    Indian J Pathol Microbiol; 2011; 54(3):460-3. PubMed ID: 21934203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
    Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
    Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
    Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
    Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
    Ueda J; Iwata T; Ono M; Takahashi M
    Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
    Wieczorek TJ; Krane JF
    Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
    Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
    Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
    Ruitenbeek T; Gouw AS; Poppema S
    Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.